Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05856058 | To Assess SHR0302 Oral Solutions and Tablets in Healthy Subjects Clinical Studies of Relative Bioavailability | PHASE1 | COMPLETED | 16 | — | — | May 29, 2023 | Oct 9, 2023 | Dec 8, 2023 | 1 | China |
| Arm | Type | Description |
|---|---|---|
| Treatment group ARM 1 | EXPERIMENTAL | SHR0302 tablets, then SHR0302 oral solution |
| Treatment group ARM 2 | EXPERIMENTAL | SHR0302 oral solution, then SHR0302 tablets |
| Name | Type | Description |
|---|---|---|
| SHR0302 | DRUG | SHR0302 oral solution 1 time, SHR0302 tablets 1 time |
Inclusion Criteria: 1. Voluntarily sign the informed consent form before the start of the activities related to the trial, and be able to understand the procedures and methods of the trial, and be willing to strictly abide by the clinical trial protocol to complete the trial; 2. Age 18\~45 years ol...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Incyte Corporation | INCY | 11 | PHASE3 | INCA034176, Tacrolimus, Methotrexate, Ruxolitinib, Cyclophosphamide |
| Sanofi SA Sponsored ADR | SNY | 2 | PHASE3 | Belumosudil, Prednisone, Prednisolone |
| Johnson & Johnson | JNJ | 1 | PHASE3 | Ibrutinib |
| Syndax Pharmaceuticals Inc | SNDX | 1 | PHASE2 | Axatilimab |
| Theriva Biologics, Inc. | TOVX | 1 | PHASE1 | Undisclosed |
| Novartis AG Sponsored ADR | NVS | 1 | — | Undisclosed |